MRMehdi Rajabi

Mehdi Rajabi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehdi Rajabi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Faezeh Monji

    Department of Clinical Pharmacy Faculty of Pharmacy Tehran Medical Sciences Islamic Azad University Tehran Iran

    2 shared publications
  • Hooman Bakhshandeh

    Department of Epidemiology, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Parvin Mansouri

    Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Abdol Ali Shahrasbi

    1 shared publication
  • Ariandokht Einisadr

    Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

    1 shared publication
  • Azadeh Nasrollah

    Department of Clinical Pharmacy, Islamic Azad University Pharmaceutical Sciences Branch, Tehran, Iran

    1 shared publication

Latest Publications

  • Assessment of thyme honey oral gel for the prevention of adriamycin and cyclophosphamide chemotherapy-induced oral mucositis in patients with breast cancer

    by Elnaz Jahanbani Mazraeh, Sanambar Sadighi, Soheila Manifar, Hooman Bakhshandeh, Mehdi Rajabi

    Purpose Oral mucositis (OM) is a common complication of cancer treatment that has an impact on a patient’s quality of life and the outcome of cancer therapy. This trial evaluated the effect of thyme honey oral gel for the prevention of chemotherapy-induced OM. Methods One hundred ten breast cancer patients who received their first cycle of chemotherapy with adriamycin (60 mg/m2) and cyclophosphamide (600 mg/m2) were randomly recruited into two groups: group A were patients who followed general oral hygiene recommendations and rinsing saline 3 times a day, and group B were patients with similar protocol but supplied with our formulated oral gel to be applied 2 to 4 times a day. Patients were assessed by the World Health Organization (WHO) oral mucositis grading scales and self-assessment daily questionnaire. Results The use of thyme honey was associated with diminishing incidence of OM grade ≥ 2 (95% CI, 0.12 to 0.90; P = 0.030), duration of OM (− 3.36 days; 95% CI, − 5.50 to − 1.22; P = 0.037) and delayed occurrence of OM grade ≥ 2 (95% CI, 0.10 to 0.80; P = 0.017). Conclusion Thyme honey can be considered as a prophylactic agent for OM and decrease the severity of its symptoms. Trial registrations This protocol was registered at the Iranian Registry of Clinical Trials: registration number IRCT201506063106N25, on June 12, 2015; approved by the institutional review board at the Deputy of Research, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran; and approved by the Ethics Committee of Medical Researches of Pharmaceutical Sciences Branch of Islamic Azad University, Tehran, Iran—reference number 5936, on August 17, 2014.


  • Therapeutic effects of turmeric topical cream in vitiligo: A randomized, double‐blind, placebo‐controlled pilot study

    by Samin Jalalmanesh, Parvin Mansouri, Mehdi Rajabi, Faezeh Monji

    Background: Vitiligo is an autoimmune and acquired disease characterized by the destruction of epidermal melanocytes leading to depigmentation of the skin. Although vitiligo is a common disease, there is not a definite cure and conventional therapies can lead to serious adverse effects. Turmeric has been widely studied for its anti‐inflammatory, antioxidant, and anti‐cell proliferation, while it is a cost‐benefit and available treatment for a variety of diseases.Aims: The aim of this study was to evaluate the efficacy of topical turmeric cream on vitiligo's lesion appearance including size and repigmentation.Patients/Methods: Following the screening, 30 patients were enrolled according to inclusion criteria. The patients received training to apply turmeric and placebo cream at the specified side of their body twice a day for 4 months. Patients were evaluated at the baseline and at monthly intervals to access possible side effects. Lesion size, vitiligo area scoring index (VASI), vitiligo noticeability scale (VNS), and physician global assessment (PGA) were evaluated at the baseline and after four months to compare the changes induced by turmeric and placebo cream.Results: Twenty‐four patients completed the trial. Applying turmeric cream reduced the size of lesions and improved lesion's appearance significantly compared to the placebo group (p < 0.001), and also, patient's satisfaction score was higher following applying turmeric cream compared to placebo (p < 0.05).Conclusions: Turmeric cream can be used as an alternative remedy or adjuvant therapy in mild to moderate vitiligo lesions and in those who cannot tolerate the adverse effects of conventional therapies.


  • Impact of rapid correction of vitamin D deficiency in asthmatic patients

    by Ariandokht Einisadr, Mehdi Rajabi, Hamidreza Moezzi, Hooman Bakhshandeh

    Summary Background Asthma is one of the most common chronic diseases, which is a growing public health concern worldwide. In recent years, there has been an increasing number of interests in the relationship between vitamin D level and asthma control. Hence, the objective of this study was to assess the effect of high doses of vitamin D3 injection on asthmatic patient’s respiratory condition and quality of life. Methods This was a single arm, before and after interventional study involving 18 patients with moderate to severe asthma. Spirometry test, St George’s respiratory questionnaire (SGRQ) and serum vitamin D assay were performed. Subjects with 25-hydroxyvitamin D3 (25-(OH) D3) < 20 ng/ml were deemed deficient (n = 18) and received 2 intramuscular injections of vitamin D3 300,000 IU at monthly intervals consecutively. Results The mean changes of forced expiratory volume in the first second (FEV1) were significantly different in subjects who received vitamin D3 injections (p = 0.008). Also, the mean changes in FEV1/forced vital capacity ratio (FEV1/FVC) were significant (p < 0.001) as well as maximum expiratory flow between 25% and 75% of FVC (MEF25-75) (p = 0.001). Interestingly, improvement in clinical parameters of SGRQ was also observed with significant differences in total score (p = 0.001). Naturally, serum vitamin D levels were increased in our patients following the injections (p < 0.001). Conclusions Our findings suggest that screening for serum 25-(OH) D3 deficiency is important in asthmatic patients and correction of this deficiency with high doses of vitamin D3 injection may lead to improvement in pulmonary function, symptoms and quality of life (QOL).


  • The efficacy and safety of permethrin 2.5% with tea tree oil gel on rosacea treatment: A double‐blind, controlled clinical trial

    by Elnaz Ebneyamin, Parvin Mansouri, Mehdi Rajabi, Mahnaz Qomi, Ramin Asgharian, Zahra Azizian

    Background: Rosacea is a chronic skin condition that typically affects the face and it results in redness and inflammation. The main risk factors of this disease are Demodex folliculorum, living in the pilosebaceous units.Aims: To evaluate the efficacy and safty of permethrin 2.5% in combination with tea tree oil (TTO) topical gel versus placebo on Demodex density (Dd) and clinical manifestation using standard skin surface biopsy (SSSB) in rosacea patients.Patient/Methods: In this double‐blind, randomized clinical trial, 47 papulopustular rosacea patients were enrolled, with 35 patients finishing the 12 weeks of treatment. Each patient used permethrin 2.5% with TTO on one side of the face and a placebo on the other, twice daily for 12 weeks. SSSB, photography and clinical rosacea scores according to National Rosacea Society, as well as adverse drug reaction (ADRs) were reported at the baseline, 2nd, 5th, 8th, and 12th weeks.Results: A total of 47 patients were enrolled with papulopustular rosacea, and 35 patients finished the study. The effects of permethrin 2.5% with TTO gel on mite density were significant at week 5, 8, 12 (P value = .001). Clinical features and global assessments showed papules, pustules and nontransient erythema had improvement in drug group after 12 weeks (P values <.05). The improvement of burning and stinging and dry appearance was greater than the placebo gel (P value <.05). Itching in placebo group was significantly more than other group (P value = .002).Conclusion: Administration of permethrin 2.5% with TTO gel demonstrated good efficacy and safety in rosacea. This topical gel inhibited the inflammatory effects of rosacea and reduced Demodex mite.


  • Efficacy and safety of permethrin 5% topical gel vs. placebo for rosacea: a double‐blind randomized controlled clinical trial

    by K. Raoufinejad, P. Mansouri, M. Rajabi, Z. Naraghi, R. Jebraeili

    Background: Rosacea is a chronic, multifactorial, dermatological condition. Increased density of Demodex folliculorum mites in the skin of rosacea patients suggests a possible role for these mites in the pathophysiology of rosacea.Objective: To evaluate the effects of permethrin 5% topical gel vs. placebo on Demodex density (Dd) and clinical presentations of rosacea patients, and also to further refine the quantitative assessment of Dd in the non‐invasive standard skin surface biopsy (SSSB).Methods: Twenty patients with bilateral papulopustular rosacea and ≥5 mites/cm2 were enrolled in the study. Participants and physicians were blinded to the group assignments. Each patient applied permethrin on one side and placebo on the other side of the face twice daily for 12 weeks. SSSB and photography and Rosacea Clinical Scorecard of the National Rosacea Society were used to assess the patients at the baseline, 2nd, 5th, 8th, and 12th weeks for both sides of the face. Causality and severity of adverse drug reactions (ADRs) were assessed by WHO Scale and Hartwig Scale, respectively.Results: Dd was not significantly different between the two groups at the baseline. In both groups, Dd significantly decreased after 12 weeks compared to the baseline. At the end of the 12th week, the Dd in the permethrin group was significantly lower than the placebo group. Severity of the clinical presentations decreased in both groups at the end of week 12 in comparison to the baseline, particularly in the permethrin group. ADRs were all mild and in most cases unlikely related to permethrin.Conclusion: Permethrin 5% gel can significantly reduce the Dd and severity of presentations in rosacea patients and can be a safe and effective option in the management of this chronic disorder. This new SSSB technique offers an easy, quick, inexpensive, and non‐invasive sampling method proper for quantitative assessment of Dd.


  • Open Access

    Impact of socioeconomic and environmental factors on atopic eczema and allergic rhinitis: a cross sectional study

    by Yasamin Torfi, Niloofar Bitarafan, Mehdi Rajabi

    The prevalence of allergic rhinitis and atopic eczema is on the rise in recent decades. Many factors can be related to the development of these diseases. We aimed to investigate the association between socioeconomic status (SES), environmental risk factors and these conditions. In this study, the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire was translated and validated. Then it was used to determine the prevalence, severity and possible related factors for both diseases in 1904 schoolchildren aged 6-7 and 13-14 years from various regions of Tehran. The prevalence of rhinitis and eczema in the past year was 33.2 % and 8.2 %, respectively. The prevalence of rhinoconjunctivitis in the past year was 30 %. The risk factors such as birth order, nursery attendance, pet ownership, past allergic experiences as well as some SES factors were associated with both conditions. The prevalence of allergic rhinitis and atopic eczema was on the rise in comparison to the previous studies and SES as well as environmental factors are thought to be associated with the prevalence of these conditions.


    • 1 January 2015
      • Vol. 14  (3) , 865-76
    Open Access

    Topical Turmeric Microemulgel in the Management of Plaque Psoriasis; A Clinical Evaluation.

    by Golnaz Sarafian, Minoo Afshar, Parvin Mansouri, Jinous Asgarpanah, Kosar Raoufinejad, Mehdi Rajabi

    Psoriasis is an autoimmune and recurrent chronic inflammatory skin disease. About 1-3% of the world wide populations are affected. The characteristic features are hyperprolifration of keratinocytes leading to redness, thickening and scaling of epidermis followed with itching and appearance of the lesions which in most cases bother the patients medically and psychologically. Psoriasis is symptomatically treated by the range of oral and topical medications, however, major side effects in some cases are associated with them. Based on several studies, Curcuma longa can inhibit several inflammatory enzymes mainly involved in the inflammatory process of Psoriasis. Therefore, we decided to target this well-known herbal agent with fantastic safety profile to be formulated as a novel topical microemulgel. The clinical and therapeutic benefit of this novel topical formulation was evaluated on 34 patients with mild to moderate plaque psoriasis in a randomized, prospective intra-individual, right-left comparative, placebo-controlled, double-blind clinical trial. The Dermatology Life Quality Index (DLQI) Questionnaire and Psoriasis area & severity index (PASI) score as well as photos before and after treatment was used to evaluate the outcomes. The results show that the clinical and quality of life parameters in treated lesions in comparison with untreated lesions have improved (P<0.05). The reported side effects were also recorded and were trivial. Based on our findings, the proposed microemulgel may well be considered as an alternative in some patients and most likely as an add-on therapeutic option for many patients suffering with plaque psoriasis.


    • 7 May 2013
      • Vol. 12, 384-95

    Irrational antibiotic prescribing: a local issue or global concern?

    by Shiva Hashemi, Azadeh Nasrollah, Mehdi Rajabi

    Resistance to antibiotics is a major public-health concern and antibiotic use is being ever more recognized as the main discriminatory pressure driving this resistance. The aim was to assess the outpatient usage of antibiotics in teaching hospitals in various parts of capital city of Iran, Tehran and its association with resistance. 600 outpatient antibiotic prescriptions between December 2011 and May 2012 were reviewed in our teaching hospitals. All prescriptions were scrutinized in order to evaluate the antibiotic prescribing. The medical doctors from all grades were asked to note the chief complaints and the most possible diagnosis on each prescription. Clinical data, patient demographic and ultimately the total quantities of antibiotics were recorded. Our data was then compared against the major antibiotic guidelines and similar studies in other countries. The most common prescribed antibiotics are Penicillins (Penicillin, Co-Amoxiclav and Amoxicillin) (40 %), Cephalosporins (Cefixime, Cephalexin and Ceftriaxone) (24.5 %) and Macrolides (particularly Azithromycin) (15.3 %). In total, 18.2 % of cases were combinational antibacterial therapies (≥ 2). The most common diagnosis was upper respiratory tract infections as common cold (29.2 %) and sore throat (11.8 %). Directions (instructions for use) of 58 % of selected antibiotics were acceptable. Parenteral administration remains the common route of administration with 22 % of all reviewed prescriptions. Based on Cochrane reviews the antibiotic prescribing was unjustified in 42.7 % of the cases. The prescribing habit, correct diagnosis and the use of antibiotics need instant consideration. These data can provide useful information for assessing public-health policy that aims to reduce the antibiotic use and resistance levels.


  • Risks to health professionals from hazardous drugs in Iran

    by Abdol Ali Shahrasbi, Minoo Afshar, Farnaz Shokraneh, Faezeh Monji, Mahjabin Noroozi, Maryam Ebrahimi-Khojin, Seyed Farzam Madani, Mehdi Ahadi-Barzoki, Mehdi Rajabi